TAUVID Drug Patent Profile

Which patents cover Tauvid, and when can generic versions of Tauvid launch?

Tauvid is a drug marketed by Avid Radiopharms Inc and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-eight patent family members in eighteen countries.

The generic ingredient in TAUVID is flortaucipir f-18. One supplier is listed for this compound. Additional details are available on the flortaucipir f-18 profile page.

DrugPatentWatch^® Generic Entry Outlook for Tauvid

Tauvid was eligible for patent challenges on May 28, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 26, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for TAUVID

International Patents:	28
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	4
Clinical Trials:	9
Patent Applications:	68
What excipients (inactive ingredients) are in TAUVID?	TAUVID excipients list
DailyMed Link:	TAUVID at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TAUVID

NDA:

212123

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TAUVID

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Cleveland Clinic	Phase 1
Avid Radiopharmaceuticals	Phase 2
Avid Radiopharmaceuticals	Phase 1

See all TAUVID clinical trials

US Patents and Regulatory Information for TAUVID

TAUVID is protected by one US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Avid Radiopharms Inc	TAUVID	flortaucipir f-18	SOLUTION;INTRAVENOUS	212123-001	May 28, 2020		DISCN	Yes	No				Y
Avid Radiopharms Inc	TAUVID	flortaucipir f-18	SOLUTION;INTRAVENOUS	212123-004	Jul 1, 2022		RX	Yes	Yes				Y
Avid Radiopharms Inc	TAUVID	flortaucipir f-18	SOLUTION;INTRAVENOUS	212123-002	May 28, 2020		DISCN	Yes	No				Y
Avid Radiopharms Inc	TAUVID	flortaucipir f-18	SOLUTION;INTRAVENOUS	212123-003	Jul 1, 2022		RX	Yes	Yes				Y

International Patents for TAUVID

When does loss-of-exclusivity occur for TAUVID?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

Colombia

Croatia

Cyprus

Denmark

European Patent Office

Finland

Hungary

Japan

Lithuania

Poland

Portugal

Slovenia

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TAUVID around the world.

Country	Patent Number	Title	Estimated Expiration
China	107011342
Spain	2792830
European Patent Office	2599763
Poland	2247558

Market Dynamics and Financial Trajectory for Tauvid (Flortaucipir F18)

Last updated: February 20, 2026

What Is Tauvid, and What Is Its Market Position?

Tauvid (flortaucipir F18) is a radioactive diagnostic agent used in positron emission tomography (PET) imaging to detect tau protein tangles in the brain. It is primarily approved for imaging tau pathology in Alzheimer's disease (AD) patients. Approved by the U.S. Food and Drug Administration (FDA) in May 2020, Tauvid addresses unmet needs in early and differential diagnosis of AD.

It is manufactured by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company. The drug holds patent protection until 2032, positioning it as a key diagnostic tool within the AD imaging market.

Market Size and Growth Projections

The global neuroimaging tracers market was valued at approximately $4.2 billion in 2022. The segment focusing on tau PET agents was estimated at around $500 million in 2022, with rapid growth expected as AD diagnostic tools expand.

Forecasts anticipate a compound annual growth rate (CAGR) of 12-15% from 2023 to 2030 for tau PET imaging agents, driven by increasing prevalence of AD and advances in neuroimaging technology.

Key Market Drivers

• Rising prevalence of Alzheimer's disease: Globally, AD affects approximately 55 million people as of 2023, expected to rise to 78 million by 2030 [1].
• Need for accurate diagnosis: Tau PET imaging provides better differential diagnosis compared to amyloid PET or clinical assessments alone.
• Regulatory advancements: Approvals of tau tracers in major markets (FDA, EMA, Japan) expand adoption.
• Reimbursement policies: Several health systems now reimburse tau PET scans, with more expected.

Market Challenges

• High cost of imaging procedures: PET scans with tracers like Tauvid can cost between $2,000 and $4,000, limiting widespread use initially.
• Limited access to PET imaging centers: Availability remains concentrated in advanced healthcare facilities.
• Competition: Other tau PET tracers are in development, and amyloid imaging remains prevalent.

Revenue Generation and Financial Performance

Eli Lilly's initial sales of Tauvid in the U.S. are estimated at $15-20 million in 2022, with projections reaching $40-60 million in 2023. Uptake remains gradual, hindered by limited awareness and infrastructure.

International sales, particularly in Europe and Asia, are in initial deployment stages. Europe's strong regulatory environment for similar diagnostics could accelerate sales, but reimbursement pathways are still evolving.

Pricing and Reimbursement Dynamics

• U.S. Medicare covers tau PET imaging for specific criteria, contributing to revenue stability.
• In Europe, reimbursement varies by country, affecting adoption rates.
• Pricing strategies aim to balance affordability with R&D recovery.

Cost Structure and Investment

• Lilly invests in expanding access and awareness campaigns.
• R&D expenditures on next-generation tau imaging agents are ongoing, with estimates around $50 million annually for related projects.

Competitive Landscape

• Lilly/Tauvid: First FDA-approved tau PET agent, leading in initial market share.
• Fujifilm: Developing tau PET agents, with regulatory submissions underway.
• R&D pipeline: Several biotech firms, such as Roche and Neurology-focused startups, are exploring alternative tau imaging compounds.

Market entry timing, reimbursement policies, and clinical adoption influence market share distribution. As of 2023, Tauvid holds approximately 60-70% of the U.S. tau PET imaging market share.

Future Outlook

The market is expected to grow substantially with increased clinical validation and expanded reimbursement. The development of more cost-effective, high-specificity tau tracers could challenge Tauvid’s dominance, but current patent protections and Lilly’s marketing efforts provide a significant advantage.

The global spread of tau imaging adoption hinges on regulatory approvals in China, Japan, and emerging markets. Investment in infrastructure and physician education will significantly determine the market trajectory.

Key Takeaways

• Tauvid is a pioneering tau PET imaging agent approved in the U.S. in 2020, targeting AD diagnosis.
• The tau PET imaging market is projected to grow at 12-15% CAGR through 2030, driven by rising AD prevalence and technological advances.
• Initial sales are modest but expected to increase as access expands; 2022 U.S. sales estimated at $15-20 million.
• Reimbursement policies and infrastructure development significantly influence market penetration.
• Competition and next-generation agents could reshape market share dynamics, though patents and regulatory approvals will sustain Lilly’s position.

FAQs

1. What factors will most influence Tauvid's future sales?
Reimbursement expansion, increased clinical adoption, infrastructure growth, and the development of competing tau tracers.

2. How does Tauvid compare to amyloid PET imaging tools?
Tauvid provides structural insights by visualizing tau tangles directly, offering more specific diagnostic information than amyloid PET, which visualizes amyloid plaques.

3. What are the primary global markets for Tauvid?
The U.S., Europe, and Japan are primary; emerging markets are in early adoption stages.

4. Which regulatory hurdles remain for Tauvid in international markets?
Reimbursement approval and clinical guideline integration are primary. Regulatory approval timelines vary by country.

5. How might new competitive agents impact Tauvid's market position?
Emerging agents with better specificity, cost advantages, or wider reimbursement coverage could reduce Tauvid's market share over time.

---

References
[1] Alzheimer's Association. (2023). 2023 Alzheimer's Disease Facts and Figures. Retrieved from https://alz.org/media/Documents/alzheimers-facts-and-figures.pdf